WO2007081808A2 - Composes et derives pour le traitement d’etats medicaux par modulation de l’activite de la lipase hormono-sensible - Google Patents

Composes et derives pour le traitement d’etats medicaux par modulation de l’activite de la lipase hormono-sensible Download PDF

Info

Publication number
WO2007081808A2
WO2007081808A2 PCT/US2007/000284 US2007000284W WO2007081808A2 WO 2007081808 A2 WO2007081808 A2 WO 2007081808A2 US 2007000284 W US2007000284 W US 2007000284W WO 2007081808 A2 WO2007081808 A2 WO 2007081808A2
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
group
unsubstituted
saturated
hydrogen
Prior art date
Application number
PCT/US2007/000284
Other languages
English (en)
Other versions
WO2007081808A3 (fr
Inventor
Jean-Frederic Sauniere
Yat Sun Or
Original Assignee
Deviris Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deviris Inc. filed Critical Deviris Inc.
Priority to AU2007205147A priority Critical patent/AU2007205147A1/en
Priority to EP07717778A priority patent/EP2015763A2/fr
Publication of WO2007081808A2 publication Critical patent/WO2007081808A2/fr
Publication of WO2007081808A3 publication Critical patent/WO2007081808A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to compounds, compositions containing them, and their use for treating medical disorders where it is desirable to decrease the activity of hormone- sensitive lipase.
  • the overall energy homeostasis of a mammalian system requires a high degree of regulation to ensure the availability of the appropriate substrate at the appropriate time.
  • Plasma glucose levels rise during the post-prandial state, to return to pre-prandial levels within 2-3 hours.
  • insulin promotes glucose uptake by skeletal muscle and adipose tissue and decreases the release of free fatty acids (FFA) from adipocytes, to ensure that the two substrates do not compete with each other.
  • FFA free fatty acids
  • FFA levels do not fall in response to insulin, as they do in normal individuals, preventing the normal utilization of glucose by skeletal muscle, adipose and liver. Furthermore, there is a negative correlation between insulin sensitivity and plasma FFA levels.
  • HSL Hormone-sensitive lipase
  • adipocytes that catalyses the conversion of triglycerides to glycerol and fatty acids. It is through the regulation of this enzyme that the levels of circulating FFA are modulated. Insulin leads to the inactivation of HSL with a subsequent fall in plasma FFA levels during the post-prandial state, followed by the activation of the enzyme when the insulin concentration falls and catecholamines rise during the post-absorptive period. The activation of HSL leads to an increase in plasma FFA, as they become the main source of energy during fasting.
  • HSL activation-inactivation of HSL is primarily mediated through the cAMP-protein kinase A and AMP-dependent kinase pathways.
  • cAMP-protein kinase A a compound like nicotinic acid and its derivatives, which decrease the activation of HSL via these pathways and cause a decrease in lipolysis that leads to a reduction in the FFA levels.
  • nicotinic acid and its derivatives which decrease the activation of HSL via these pathways and cause a decrease in lipolysis that leads to a reduction in the FFA levels.
  • These drugs have a beneficial effect in the utilization of glucose and in the normalization of the excess triglyceride synthesis seen in patients with elevated FFA. However, because these pathways are used by other processes in the body, these drugs have severe side effects.
  • the invention relates to oleocanthals, the general structure of which is as follows, and derivatives thereof:
  • Oleocanthal also known as deacetoxyligstroside aglycon
  • the present invention relates to oleocanthal derivatives, analogs, and homologs of oleocanthal and related compounds, particularly prodrug derivatives of oleocanthal, analogs, and homologs, and related compounds, pharmaceutical compositions thereof, and to methods of using such derivatives and pharmaceutical compositions thereof in the treatment of disease. It has been discovered that the oleocanthals have anti-HSL activity and that the oleocanthals and their analogs and homologs and their prodrug derivatives, set forth in the compound of formulae I and II, have shown a strong inhibitory effect on the lipolytic activity of HSL and lead to a decrease in plasma FFA levels.
  • the oleocanthal is para- hydroxyphenylelenolic acid dialdehyde (p-HPEA-EDA) (fraction O-4456) and 3,4- dihydroxyphenylelenolic acid dialdehyde (3,4-DHPEA-EDA) (fraction O-4457) as well as other compounds disclosed herein.
  • p-HPEA-EDA para- hydroxyphenylelenolic acid dialdehyde
  • 3,4-DHPEA-EDA 3,4- dihydroxyphenylelenolic acid dialdehyde
  • these compounds can be used to treat disorders where a decreased level of plasma FFA is desired, such as insulin resistance, metabolic syndrome X, dyslipidemia, and abnormalities of lipoprotein metabolism.
  • the present invention is directed to the compound(s) of formula I and salts, solvates and hydrates, racemates, racemic mixtures and pure enantiomers, diastereomers, homologs, analogs and mixtures thereof,
  • R is hydrogen, hydroxyl or -OR 1 ; wherein R 1 is hydrogen or a chemical moiety that can be cleaved in vivo to release a hydroxyl group and includes, for example, aliphatic or aromatic acyl (to form an ester bond) and the like.
  • Such aliphatic or aromatic groups can include a substituted or unsubstituted, saturated or unsaturated aliphatic group, a substituted or unsubstituted, saturated or unsaturated alicyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or a substituted or unsubstituted heterocyclic group, a carbalkoxy, a carbaryloxy, -SO 3 H and -SO 3 R 3 , -P(O)(OH) 2 , or -P(O)(OR 3 ) 2 ; wherein R 3 is a saturated or unsaturated aliphatic group, substituted or unsubtituted aliphatic group, substituted or unsubstituted saturated or unsaturated alicyclic group, substituted or unsubstituted aromatic group, substituted or unsubstituted heteroaromatic group, substituted or unsubstituted heterocyclic group,
  • the present invention is directed to the prodrug derivative of formula I 7 which is set forth below in formula IT, and salts, solvates and hydrates, racemates, racemic mixtures and pure enantiomers, diastereomers, homologs, analogs and mixtures thereof,
  • R, R 1 , R 3 , Y and Z are as previously defined; and, wherein wherein R 2 is hydrogen or a hydroxyl protecting group, as described in "Protective Groups in Organic Synthesis" by Therodora W. Greene, Peter G.M.Wuts, 1999, 3 rd edition, pp 17 — 200, -SO 3 H and — SO 3 R 3 where R 3 is a saturated or unsaturated aliphatic group; a substituted or unsubstituted saturated or unsaturated alicyclic group.
  • the invention also provides isolated and purified compounds of formulae (I) and (11), wherein R is hydrogen, hydroxyl or -OR 1 , wherein R 1 is hydrogen, -OC(O), a carbalkoxy, a carbaryloxy, R 4 , OR 5 , SO 3 H, SO 3 R 3 , P(O)(OH) 2 , P(O)(OR 3 ) 2 , glucuronide, or glucuronide ester, wherein R 2 is hydrogen, P, SO 3 H, SO 3 R 3 , P(O)(OH) 2 , P(O)(OR 3 ) 2 , glucuronide, glucuronide ester, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, wherein R 3 is alkyl,
  • the invention provides compounds comprising one or more of the isolated and purified compounds of formulae (I) and (II) wherein when Y is -OC(O)-, when Z is H and when R is hydrogen, R 1 is not hydrogen; and wherein when Y is -OC(O)-, when Z is H and when R is hydroxyl, R 1 is not hydrogen.
  • the invention also provides pharmaceutical compositions comprising one or more of the isolated and purified compounds of formulae (I) and (II) wherein when Y is -OC(O)-, when Z is H and when R is hydrogen, R 1 is not hydrogen; and wherein when Y is -OC(O)-, when Z is H and when R is hydroxyl, R 1 is not hydrogen and a pharmaceutically acceptable carrier.
  • the invention provides a method of inhibiting hormone-sensitive lipase in a patient in need thereof comprising administering to said patient one or more of the isolated and purified compounds of formulae (I) and (II), optionally in combination with one or more active ingredients which have favorable effects on metabolic disturbances or disorders, such as anti-diabetic drugs or lipid modulators.
  • the invention provides a method of treating or preventing one or more symptoms associated with disorders of fatty acid metabolism and glucose utilization disorders in a patient in need thereof comprising administering to said patient a therapeutically effective amount of one or more of the isolated and purified compounds of formulae (T) and (II), optionally in combination with at least one further active ingredient for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders.
  • the invention provides a method of treating or preventing disorders involving insulin resistance, such as diabetes mellitus, comprising administering to said patient a therapeutically effective amount of one or more of the isolated and purified compounds of formulae (I) and (II), optionally in combination with at least one further active ingredient for the treatment and/or prevention of disorders in which insulin resistance is involved.
  • the invention provides a method of treating or preventing dyslipidemias and their complications comprising administering to said patient a therapeutically effective amount of one or more of the isolated and purified compounds of formulae (I) and (II).
  • the invention provides a method of treating or preventing conditions associated with metabolic syndrome X, comprising administering to said patient a therapeutically effective amount of one or more of the isolated and purified compounds of formulae (1) and (II).
  • the present invention provides pharmaceutical compositions comprising one or more of the isolated and purified compounds of formulae (I) and (II) in a pharmaceutically acceptable carrier, methods of using the isolated and purified compounds, homologs, biologically active analogs and pharmaceutical compositions thereof in the treatment of various disorders caused by an increase of hormone sensitive lipase.
  • Figure 1 indicates the percentage of inhibitory activity of anti-HSL fractions (O-
  • Figure 2 indicates the percentage of inhibitory activity of anti-HSL fractions (O- 4354, O-4355 and O-4361) in the absence of DTT.
  • Figure 3 indicates the percentage of inhibitory activity of anti-HSL fractions (O- 4356, O-4357, O-4358, O-4359 and O-4360) in the absence of DTT.
  • Figure 4 indicates the percentage of inhibitory activity of anti-HSL fractions (O- 4349, O-4351, O-4352, and O-4353) in the absence of DTT.
  • Figure 5 indicates the percentage of inhibitory activity of anti-HSL fractions (O- 4363, O-4362, O-4364, and O-4365) in the absence of DTT.
  • Figure 6 indicates the percentage of inhibitory activity of anti-HSL fractions (O- 4354, O-4348, O-4366, and O-4367) in the absence of DTT.
  • Figure 7 indicates the percentage of inhibitory activity of an anti-HSL fraction (O- 4355) and a control (HSL+DMSO) in the absence of DTT.
  • Figure 8 indicates the percentage of inhibitory activity of an anti-HSL fraction (O- 4350) in the absence of DTT.
  • Figure 9 indicates the percentage of inhibitory activity of an anti-HSL fraction (O- 4361) in the absence of DTT.
  • An "aliphatic group” is non-aromatic moiety that may contain any combination of carbon atoms, hydrogen atoms, halogen atoms, oxygen, nitrogen or other atoms, and optionally contain one or more units of unsaturation, e.g., double and/or triple bonds.
  • An aliphatic group may be straight chained, branched or cyclic and preferably contains between about 1 and about 24 carbon atoms, more typically between about 1 and about 12 carbon atoms.
  • aliphatic groups include, for example, alkoxyalkyls, polyalkoxyalkyls, such as polyalkylene glycols, polyamines, and polyimines, for example. Such aliphatic groups may be further substituted by one or more aliphatic substituents.
  • aryl or “aromatic,” as used herein, refer to a mono- or bicyclic carbocyclic ring system having one or two aromatic rings including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, idenyl and the like.
  • substituted aryl or “substituted aromatic” as used herein, refer to an aryl group, as previously defined, substituted by one, two, three or more aromatic substituents.
  • heteroaryl or “heteroaromatic,” as used herein, refer to a mono-, bi-, or tri-cyclic aromatic radical or ring having from five to ten ring atoms of which at least one ring atom is selected from S, O and N; zero, one, two, three or more ring atoms are additional heteroatoms independently selected from S, O and N; and the remaining ring atoms are carbon, wherein any N or S contained within the ring may be optionally oxidized.
  • Heteroaryl includes, but is not limited to, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzooxazolyl, quinoxalinyl, tetrazolyl and the like.
  • the heteroaromatic ring may be bonded to the chemical structure through a carbon or hetero atom.
  • substituted heteroaryl or “substituted heteroaromatic,” as used herein, refer to a heteroaryl group as previously defined, substituted by one, two, three or more aromatic substituents.
  • alicyclic denotes a monovalent group derived from a monocyclic or bicyclic saturated carbocyclic ring compound by the removal of a single hydrogen atom. Examples include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo [2.2.1] heptyl, and bicyclo [2.2.2] octyl.
  • substituted alicyclic as previously defined, substituted by one, two, three or more aliphatic substituents.
  • heterocyclic refers to a non-aromatic 5-, 6- or 7- membered ring or a bi- or tri-cyclic group fused system, where (i) each ring contains between one and three heteroatoms independently selected from oxygen, sulfur and nitrogen, (ii) each 5-membered ring has 0 to 1 double bonds and each 6-membered ring has 0 to 2 double bonds, (iii) the nitrogen and sulfur heteroatoms may optionally be oxidized, (iv) the nitrogen heteroatom may optionally be quaternized, (iv) any of the above rings may be fused to a benzene ring, and (v) the remaining ring atoms are carbon atoms which may be optionally oxo-substituted.
  • heterocycloalkyl groups include, but are not limited to, [l,3]di oxo lane, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinonyl, tetrahydrofuryl, and the like.
  • substituted heterocyclic refers to a heterocyclic group, as previously defined, substituted by one, two, three or more aliphatic substituents.
  • Suitable aliphatic or aromatic substituents include, but are not limited to, -F 7
  • the term "pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977).
  • the salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable organic acid or inorganic acid.
  • nontoxic acid addition salts include, but are not limited to, salts of an amino group formed with inorganic acids such as ⁇ hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid lactobionic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • inorganic acids such as ⁇ hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
  • organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid lactobionic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2- naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pam
  • Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl having from 1 to 6 carbon atoms, sulfonate and aryl sulfonate.
  • pharmaceutically acceptable ester refers to esters which hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof.
  • Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms.
  • Examples of particular esters include, but are not limited to, formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.
  • prodrugs refers to those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the present invention.
  • Prodrug as used herein means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis) to a compound of Formula I.
  • prodrugs are known in the art, for example, as discussed in Bundgaard, (ed.), Design of Prodrugs, Elsevier (1985); Widder, et al. (ed.), Methods in Enzymology, vol. 4, Academic Press (1985); Krogsgaard-Larsen, et al., (ed). "Design and Application of Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-191 (1991); Bundgaard, et al., Journal of Drug Deliver Reviews, 8:1-38(1992); Bundgaard, J. of Pharmaceutical Sciences, 77:285 et seq.
  • pharmaceutically acceptable carrier is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration, such as sterile pyrogen-free water. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
  • the present invention relates to the discovery of the hormone sensitive lipase (HSL) strong inhibitory activity of the compounds set forth in formulae I and II and their derivatives, particularly prodrug derivatives, pharmaceutical compositions thereof, and to methods of using such derivatives, homologs biologically active analogs and pharmaceutical compositions thereof in the treatment of disease.
  • HSL hormone sensitive lipase
  • These compounds may be extracted from olives, olive oil, roots, bark and leaves from olea europeae species (Paiva and al., J.Agric. Food Chem., 49:4214-4219, 2001).
  • the compounds of the invention may possess pharmaceutical and chemical properties which render them superior over the natural oleocanthal, and its analogs and metabolites, as therapeutic agents.
  • the present invention relates to the discovery of anti-HSL activity of the compounds of the formulae (I) and (II)
  • R is hydrogen, hydroxyl or -OR 1 wherein R 1 is hydrogen or a chemical moiety that can be cleaved in vivo to release a hydroxyl group and includes, for example, aliphatic or aromatic acyl (to form an ester bond) and the like.
  • Such aliphatic or aromatic groups can include a substituted or unsubstituted, saturated or unsaturated aliphatic group, a substituted or unsubstituted, saturated or unsaturated alicyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or a substituted or unsubstituted heterocyclic group.
  • R 1 is -SO 3 H and -SO 3 R 3 where R 3 is a saturated or unsaturated aliphatic group; a substituted or unsubstituted saturated or unsaturated alicyclic group; -P(O)(OH) 2 , and -P(O)(OR 3 ) 2 where R 3 is as previously defined; glucuronide and esters of glucuronide, R 2 is hydrogen or a hydroxyl protecting group, as described in "Protective Groups in Organic Synthesis" by Therodora W. Greene, Peter G.M.Wuts, 1999, 3rd edition, pp 17 - 200.
  • R hydrogen or -OR 1 ;
  • R 4 is independently hydrogen, a di-substituted amino, a substituted or unsubstituted, saturated or unsaturated aliphatic group, a substituted or unsubstituted, saturated or unsaturated alicyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or a substituted or unsubstituted heterocyclic group.
  • R 4 is methyl, ethyl, propyl, isobutyl, benzyl, methylbenzyl, substituted or unsubstituted aryl; substituted or unsubstituted heterocyclic.
  • R 2 is substituted or unsubstituted saturated or unsaturated aliphatic group; substituted or unsubstituted alicylic group.
  • R 2 is — SO 3 H and — SO 3 R 3 where R 3 is a saturated or unsaturated aliphatic group; a substituted or unsubstituted saturated or unsaturated alicyclic group; -P(O)(OH) 2 , and -P(O)(OR 3 ) 2 where R 3 is as previously defined; glucuronide and glucuronide esters.
  • the compounds of the invention may possess pharmaceutical and chemical properties which render them superior over the natural oleocanthal, analogs and its metabolites as therapeutics.
  • This invention in addition to the compound of formulae (I) and (II), also contemplates the use of homologs and analogs of such compounds.
  • homologs are molecules having substantial structural similarities to the above-described compounds and analogs are molecules having substantial biological similarities regardless of structural similarities.
  • the invention also provides methods for treating conditions where a decrease and inhibition of hormone sensitive lipase (HSL) is beneficial to patients to treat disorders where a decreased level of plasma FFA is desired, such as insulin resistance, metabolic syndrome X, dyslipidemia, and abnormalities of lipoprotein metabolism.
  • HSL hormone sensitive lipase
  • the compounds of the invention of the general formulae I or II may have a strong inhibitory effect on HSL, an allosteric enzyme in adipocytes which is inhibited by insulin and is responsible for the breakdown of fats in fat cells and thus for transferring fat constituents into the blood stream. Inhibition of this enzyme is therefore equivalent to an insulin-like effect of the compounds and derivatives of the invention, eventually leading to reduction of free fatty acids in the blood and of blood glucose.
  • the compounds of formulae I or II can therefore be employed for metabolic derangements such as, for example, for non-insulin- dependent diabetes mellitus, for diabetic syndrome and for direct pancreatic damage.
  • inert solvents include, but are not limited to, chloroform, methylene chloride, tetrahydrofuran, diethylether, benzene, tolune, xylene, DMF, and N-methylpyrolidone etc.
  • the product is obtained by an aqueous work up and extracted to organic solvent and purified by chromatography, if necessary.
  • examples of appropriate base include, but are not limited to, pyridine, triethyl amine, Hunig's base, dimethylaminopyridine, CsHCO 3 , KHCO 3 , or K2CO3.
  • solvents are, but not limited to, chloroform, methylene chloride, tetrahydrofuran, diethylether, benzene, toluene, xylene, DMF, and N-methylpyrolido ⁇ e, etc.
  • the product is obtained by an aqueous work up and extracted to organic solvent and purified by chromatography, if necessary.
  • Scheme 3 shows the formation of enol-lactol by reacting oleocanthal or protected oleocanthal with acid or base in an appropriate solvent followed by aqueous work up.
  • acids include, but are not limited to, acetic acid, formic acid, lactobionic acid, malic acid, toluensulfonic acid, methansulfonic acid, dilute sulfuric acid, dilute phosphoric acid, etc.
  • bases included, but are not limited to, pyridine, dimethylaminopyridine, methylated guanidine, Hunig's base, etc.
  • Appropriate solvents include, but are not limited to, tetrahydrofuran, diethyl ether, glyme, diglyme, water, DMF, DMSO, etc.
  • examples of appropriate base include, but are not limited to, pyridine, triethyl amine, Hunig's base, dimethylaminopyridine, CsHCO 3 , KHCO 3 , OrK 2 COa.
  • appropriate solvents include, but are not limited to, chloroform, methylene chloride, tetrahydrofuran, diethylether, benzene, tolune, xylene, DMF, and N- mthylpyrolidone, etc.
  • the product is obtained by an aqueous work up and extracted to organic solvent and purified by chromatography if necessary.
  • compound (1-1) was prepared according to the literature, AB Smith et al, Organic Letters, VoI 7, No 22, 5075-5078, 2005.
  • strong base such as HMPA or tert-Butyl Lithium in appropriate solvent, followed by alkylation with corresponding amide provides compound (1-2) according to the procedures described in the above reference.
  • Y is as previously described.
  • Compound (1-2) is elaborated to the target compound according to the procedures described in the literature.
  • the compounds of the invention of the general formulae (I) and (II) have a strong inhibitory effect on hormone sensitive lipase (HSL), an allosteric enzyme in adipocytes which is inhibited by insulin and is responsible for the breakdown of fats in fat cells and thus for transferring fat constituents into the blood stream. Inhibition of this enzyme is therefore equivalent to an insulin-like effect of the compounds and derivatives of the invention, eventually leading to reduction of free fatty acids in the blood and of blood glucose.
  • HSL hormone sensitive lipase
  • These compounds can therefore be employed for metabolic derangements such as, for example, for non-insulin-dependent diabetes mellitus, for diabetic syndrome and for direct pancreatic damage.
  • Compounds of formulae (I) and (II) are particularly suitable for the treatment and/or prevention of alterations of fatty acid metabolism and glucose utilization disorders, disorders in which insulin resistance is involved, e.g., Diabetes mellitus, especially type-II diabetes, including the prevention of the complications associated therewith.
  • disorders in which insulin resistance is involved e.g., Diabetes mellitus, especially type-II diabetes, including the prevention of the complications associated therewith.
  • Particular aspects in this connection are hyperglycemia, improvement in insulin resistance, improvement in glucose tolerance, protection of the pancreatic ⁇ -cells, and prevention of macro- and microvascular disorders.
  • Compounds of formulae (I) and (II) are also suitable for the treatment and/or prevention of dyslipidemias their complications such as, for example, atherosclerosis, coronary heart disease, cerebrovascular disorders, etc, especially those (but not restricted thereto) which are characterized by one or more of the following factors: high plasma triglyceride concentrations, high postprandial plasma triglyceride concentrations, low HDL cholesterol concentration, low ApoA lipoprotein concentrations, high LDL cholesterol concentrations, small dense LDL cholesterol particles and high ApoB lipoprotein concentrations.
  • dyslipidemias their complications such as, for example, atherosclerosis, coronary heart disease, cerebrovascular disorders, etc, especially those (but not restricted thereto) which are characterized by one or more of the following factors: high plasma triglyceride concentrations, high postprandial plasma triglyceride concentrations, low HDL cholesterol concentration, low ApoA lipoprotein concentrations, high LDL cholesterol concentrations, small dense LDL cholesterol particles and high Apo
  • metabolic syndrome X 3 Various other conditions may be associated with the metabolic syndrome X 3 such as: obesity, including central obesity, thromboses, heart failure such as, for example (but not restricted thereto), following myocardial infarction, hypertensive heart disease or cardiomyopathy.
  • one or more of the compounds of general formulae (I) and (II) are useful for the treatment of hyperglycemia, elevated HbAic level, hyperinsulinemia, type II diabetes, latent autoimmune diabetes in adults, maturity onset diabetes, beta-cell apoptosis, hemochromatosis induced diabetes, impaired glucose tolerance, impaired fasting glucose, metabolic syndrome X, insulin resistance, impaired lipid tolerance, cystic fibrosis-related diabetes, polycystic ovarian syndrome, and gestational diabetes.
  • one or more of the compounds of general formulae (I) and (II) maybe useful for the treatment of Ii ver disorders, such as hepatic steatosis and cirrhosis.
  • one or more of the compounds of general formulae (I) and (II) may be useful for the treatment of symptoms such as weight loss and cachexia associated with AIDS or an AIDS related diseases.
  • conditions or disorders such as osteoarthritis; lupus erythematosus (LE) or inflammatory rheumatic disorders such as, for example, rheumatoid arthritis; vasculitis; wasting (cachexia); gout; ischemia/reperfusion syndrome acute respiratory distress syndrome (ARDS); lipodystrophy and Hpodystrophic states, also for treating adverse effects of other drugs used to treat various conditions (e.g. following medicaments for treating HIV or tumors).
  • one or more of the compounds of general formulae (I) and (II) are useful for the prevention or treatment of obesity, dyslipidemia, diabetic dyslipidemia, hyperlipidemia, hypertriglyceridemia, hyperlipoproteinemia, hypercholesterolemia, hypertension, essential hypertension, acute hypertensive emergency, arteriosclerosis, atherosclerosis, restenosis, intermittent claudication , cardiovascular disease, cardiomyopathy, cardiac hypertrophy, left ventricular hypertrophy, coronary artery disease, early coronary artery disease, heart insufficiency, exercise tolerance, chronic heart failure, mild chronic heart failure, arrhythmia, cardiac dysrythmia, syncopia, heart attack, myocardial infarction, Q- wave myocardial infarction, stroke, acute coronary syndrome, angina pectoris, unstable angina, cardiac bypass reocclusion, diastolic dysfunction, systolic dysfunction, non- Q-wave cardiac necrosis, catabolic changes after surgery, acute pan
  • one or more of the compounds of general formulae (I) and (II) may be useful for the prevention or treatment of diabetic retinopathy, background retinopathy, preproliferative retinopathy, proliferative retinopathy, macular edema, cataracts, nephropathy, nephrotic syndrome, diabetic nephropathy, microalbuminuria, macroalbuminuria, neuropathy, diabetic neuropathy, polyneuropathy, and diabetic autonomic neuropathy.
  • one or more of the compounds of general formulae (I) and (II) may be useful for the prevention or treatment of other disorders or conditions in which inflammatory reactions or cell differentiation may be involved.
  • Atherosclerosis such as, for example (but not restricted thereto), coronary sclerosis including angina pectoris or myocardial infarction, stroke vascular restenosis or reocclusion; chronic inflammatory bowel diseases such as, for example, Crohn's disease and ulcerative colitis, pancreatitis; and other inflammatory states.
  • one or more of the compounds of general formulae (I) and (II) are believed to be useful for the prevention or treatment of a disease, condition or disorder wherein cholesterol is a precursor.
  • diseases, conditions or disorders may relate to testosterone, e.g. male contraception, excessive testosterone levels, and prostate cancer. They may also relate to Cortisol or corticotropin, e.g. Cushing disease.
  • the compounds of the invention are also believed to be useful for the prevention or treatment of cancer.
  • one or more of the compounds of general formulae (I) and. (II) may be useful for the treatment of insulinoma (pancreatic islet cell tumors), e.g. malignant insulinomas and multiple insulinomas, adipose cell carcinomas, e.g. lipocarcinoma adipose .
  • pomatous carcinomas such as, for example, liposarcomas
  • solid tumors and neoplasms such as, for example (but not restricted thereto), carcinomas of the gastrointestinal tract, liver, biliary tract and pancreas; endocrine tumors; carcinomas of the lungs, kidneys, urinary tract, genital tract, and prostate.
  • the compounds of the invention are also believed to be useful for the prevention or treatment of phaechromocytoma and other diseases with increased catecholamine incretion.
  • the compounds of the invention are also believed to be useful for the prevention or treatment of prostate cancer, e.g. adenocarcinoma, acute and chronic myeloproliferative disorders and lymphomas; angiogenesis, cancer associated cachexia; neurodegenerative disorders, such as Alzheimer's disease, multiple sclerosis, and Parkinson's disease; erythemato-squamous dermatoses such as, psoriasis, acne vulgaris; and other skin disorders and dermatological conditions which are modulated by PPAR, including but not limited to, eczemas and neurodermatitis; dermatitis such as, for example, seborrheic dermatitis or photodermatiti; keratitis and keratoses such as, for example, seborrheic keratoses, senile keratoses, actinic keratosis, photo-induced keratoses or keratosis follicularis, keloids and keloid prophylaxis;
  • the compounds of the invention can be administered alone or in combination with one or more further pharmacologically active substances which have, for example, favorable effects on metabolic disturbances or disorders frequently associated therewith.
  • medicaments which lower blood glucose, anti-diabetics, active ingredients for the treatment of dyslipidemias, anti-atherosclerotic medicaments, anti-obesity agents, anti : inflammatory active ingredients, active ingredients for the treatment of malignant tumors, anti-thrombotic active ingredients, active ingredients for the treatment of high blood pressure, active ingredients for the treatment of heart failure and active ingredients for the treatment and/or prevention of complications caused by diabetes or associated with diabetes.
  • the present compounds may be administered in combination with one or more anti-hypertensive agents.
  • antihypertensive agents are ⁇ -blockers such as alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (angiotensin converting enzyme) inhibitors such as benazepril, captopril, alatriopril, enalapril, fosinopril, lisinopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and ⁇ -blockers such as doxazosin, urapidil, prazosin and terazosin. Any suitable combination of the compounds according to the invention with one or more of the above-ment
  • the one or more further pharmacologically active substances can be combined with one or more of the compounds of general formulae (I) and (II) in particular for a synergistic improvement in the effect.
  • Administration of the active ingredient combination can take place either by separate administration of the active ingredients to the patient or in the form of combination products.
  • one or more of the compounds of general formulae (I) and (II) are administered in combination -with an anti-diabetic (see, e.g., Rote Liste 2001, chapter 12 or in the USP Dictionary of USAN and International Drug Names, US Pharmacopeia, Rockville 2001).
  • Antidiabetics include all insulins and insulin derivatives and other fast-acting insulins, GLP-I receptor modulators.
  • the orally effective hypoglycemic active ingredients may include but are not limited to, sulfonylureas (such as tolbutamide, glibenclamide, glipizide or glimepiride), biguanides (such as metformin), meglitinides (such as repaglinide), oxadiazol ⁇ dinediones, thiazolidinediones (such as ciglitazone, pioglitazone, rosiglitazone), glucosidase inhibitors, glucagon antagonists, GLP-I agonists, DPP-IV inhibitors, potassium channel openers , insulin sensitizers, inhibitors of liver enzymes involved in the stimulation of gluconeogenesis and/or glycogenolysis, modulators of glucose uptake, compounds which alter lipid metabolism and lead to a change in the blood lipid composition, compounds which reduce food intake, PPAR and PXR modulators and active ingredients which act on the ATP- dependent potassium
  • one or more of the compounds of general formulae (I) and (II) are administered in combination with a PPARgamma agonist such as, for example, rosiglitazone, pioglitazone. ' - ⁇
  • a PPARgamma agonist such as, for example, rosiglitazone, pioglitazone.
  • one or more of the compounds of general formulae (I) and (II) are administered in combination with an ⁇ -glucosidase inhibitor such as, for example, miglitol or acarbose.
  • an ⁇ -glucosidase inhibitor such as, for example, miglitol or acarbose.
  • one or more of the compounds of general formulae (I) and (II) are administered in combination with more than one of the aforementioned compounds, e.g. in combination with a sulfonylurea and metformin, a sulfonylurea and acarbose, repaglinide and metformin, insulin and a sulfonylurea, insulin and metformin, insulin and troglitazone, insulin and lovastatin, etc.
  • one or more of the compounds of general formulae (I) and (II) are administered in combination with one or more lipid modulators.
  • lipid modulators include, but are not limited to, HMGCoA reductase inhibitor (such as lovastatin, fluvastatin, pravastatin, simvastatin, ivastatin, itavastatin, atorvastatin, rosuvastatin); bile acid reabsorption inhibitors; polymeric bile acid adsorbent (such as, cholestyramine, colesevelam); cholesterol absorption inhibitor (such as ezetimibe, tiqueside, pamaqueside); an LDL receptor inducer;
  • HMGCoA reductase inhibitor such as lovastatin, fluvastatin, pravastatin, simvastatin, ivastatin, itavastatin, atorvastatin, rosuvastatin
  • bile acid reabsorption inhibitors such as, cholestyramine,
  • one or more of the compounds of general formulae (I) and (II) are administered in combination with bulking agents.
  • one or more of the compounds of general formulae (I) and (II) are administered in combination with a PPARalpha agonist.
  • one or more of the compounds of general formulae (I) and (II) are administered in combination with a mixed PPAR alpha/gamma agonist such as, for example, AZ 242 .Tesaglitazar.
  • a mixed PPAR alpha/gamma agonist such as, for example, AZ 242 .Tesaglitazar.
  • one or more of the compounds of general formulae (I) and (II) are administered in combination with a fibrate such as, for example, fenof ⁇ brate, gemfibrozil, clofibrate, bezafibrate.
  • a fibrate such as, for example, fenof ⁇ brate, gemfibrozil, clofibrate, bezafibrate.
  • one or more of the compounds of general formulae (I) and (II) are administered in combination with nicotinic acid or niacin.
  • one or more of the compounds of general formulae '(I) and (II) are administered in combination with ' a CETP inhibitor alone such as, e.g. CP-529, 414 (torcetrapib) and in a multiple combination therapy including but not restricted to HMGCoA reductase inhibitor such as lovastatin, fluvastatin , pravastatin, simvastatin, ivastatin, atorvastatin, rosuvastatin.
  • one or more of the compounds of general formulae (I) and (I! are administered in combination with an ACAT inhibitor.
  • one or more of the compounds of general formulae (I) and (II) are administered in combination with an MTP inhibitor such as, for example, implitapide.
  • one or more of the compounds of general formulae (I) and (II) are administered in combination with an antioxidant.
  • one or more of the compounds of general formulae (I) and (II) are administered in combination with a lipoprotein lipase inhibitor.
  • one or more of the compounds of general formulae (I) and (II) are administered in combination with an ATP citrate lyase inhibitor.
  • one or more of the compounds of general formulae (I) and (II) are administered in combination with a squalene synthetase inhibitor.
  • one or more of the compounds of general formulae (I) and (II) are administered in combination with a lipoprotein(s) antagonist.
  • one or more of the compounds of general formulae (I) and (II) are administered in combination with an anti-obesity agent.
  • the compounds of the formula (I) or (II) are administered in . combination with a lipase inhibitor such as, for example, orlistat.
  • the further active ingredient is fenfluramine, dexfenfluramin or sibutramine.
  • one or more of the compounds of general formulae (I) and (II) are administered in combination with CART modulators, NPY antagonists, MC4 agonists, orexin antagonists , H3 agonists , TNF agonists, CRF antagonists, CRF BP antagonists , urocortin agonists, ⁇ 3 agonists , MSH (melanocyte-stimulating hormone) agonists, CCK-A agonists , serotonin reuptake inhibitors (e.g.
  • dexfenfluramine mixed serotoninergic and noradrenergic compounds
  • 5HT agonists bombesin agonists, galanin antagonists, growth hormone (e.g. human growth hormone), growth hormone-releasing compounds , TRH agonists, uncoupling protein 2 or 3 modulators, leptin agonists , DA agonists (bromocriptine, Doprexin), lipase/amylase inhibitors;, PPAR modulators , RXR modulators or TR- ⁇ agonists.
  • the further active ingredient is leptin, dexamphetamine, amphetamine, mazindole or phentermine.
  • one or more of the compounds of general formulae (I) and (II) are administered in combination with medicaments having effects on the coronary circulation and the vascular system, such as, for example, ACE inhibitors (e.g. ramipril), medicaments which act on the angiotensin-renine system, calcium antagonists, beta blockers etc.
  • medicaments having effects on the coronary circulation and the vascular system such as, for example, ACE inhibitors (e.g. ramipril), medicaments which act on the angiotensin-renine system, calcium antagonists, beta blockers etc.
  • one or more of the compounds of general formulae (I) and (II) are administered in combination with medicaments having an anti-inflamrnatory effect.
  • one or more of the compounds of general formulae (I) and (II) are administered in combination with medicaments which are employed for cancer therapy and cancer prevention.
  • medicaments which are employed for cancer therapy and cancer prevention.
  • the invention encompasses pharmaceutical compositions comprising pharmaceutically acceptable salts of the compounds, or derivatives, analogs, homologs thereof, of the invention as described above.
  • the invention also encompasses pharmaceutical compositions comprising hydrates of the compounds of the invention.
  • hydrate includes but is not limited to hemihydrate, monohydrate, dehydrate, trihydrate and the like.
  • the invention further encompasses pharmaceutical compositions comprising any solid or liquid physical form of the compound of the invention.
  • the compounds can be in a crystalline form, in amorphous form, and have any particle size. The particles may be micronized, or may be agglomerated, particulate granules, powders, oils, oily suspensions or any other form of solid or liquid physical form.
  • compositions suitable for administration can be incorporated into pharmaceutical compositions suitable for administration, together with a pharmaceutically acceptable carrier or excipient.
  • Such compositions typically comprise a therapeutically effective amount of any of the compounds above, and a pharmaceutically acceptable carrier.
  • the effective amount when treating cancer is an amount effective to selectively induce terminal differentiation of suitable neoplastic cells and less than an amount which causes toxicity in a patient.
  • Prodrugs described in formula (I) and (II) may be administered by any suitable means, including, without limitation, parenteral, intravenous, intramuscular, subcutaneous, implantation, oral, sublingual, buccal, nasal, pulmonary, transdermal, topical, vaginal, rectal, and transmucosal administrations or the like.
  • Pharmaceutical preparations include a solid, semisolid or liquid preparation (tablet, pellet, troche, capsule, suppository, cream, ointment, aerosol, powder, liquid, emulsion, suspension, syrup, injection etc.) containing an oleocanthal as an active ingredient, which is suitable for selected mode of administration.
  • the pharmaceutical compositions are administered orally, and are thus formulated in a form suitable for oral administration, i.e., as a solid or a liquid preparation.
  • suitable solid oral formulations include tablets, capsules, pills, granules, pellets, sachets and effervescent, powders, and the like.
  • Suitable liquid oral formulations include solutions, suspensions, dispersions, emulsions, oils and the like.
  • the composition is formulated in a capsule.
  • the compositions of the present invention comprise in addition to the active compound and the inert carrier or diluent, a hard gelatin capsule.
  • any inert excipient that is commonly used as a carrier or diluent may be used in the formulations of the present invention, such as for example, a gum, a starch, a sugar, a cellulosic material, an acrylate, or mixtures thereof.
  • a preferred diluent is microcrystalline cellulose.
  • compositions may further comprise a disintegrating agent (e.g., croscarmellose sodium) and a lubricant (e.g., magnesium stearate), and in addition may comprise one or more additives selected from a binder, a buffer, a protease inhibitor, a surfactant, a solubilizing agent, a plasticizer, an emulsif ⁇ er, a stabilizing agent, a viscosity increasing agent, a sweetener, a film forming agent, or any combination thereof.
  • a disintegrating agent e.g., croscarmellose sodium
  • a lubricant e.g., magnesium stearate
  • additives selected from a binder, a buffer, a protease inhibitor, a surfactant, a solubilizing agent, a plasticizer, an emulsif ⁇ er, a stabilizing agent, a viscosity increasing agent, a sweetener, a film forming agent, or any combination
  • pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, emulsions or oils.
  • non-aqueous solvents are propylene glycol, polyethylene glycol, and injectable organic esters such as ethyl oleate.
  • Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
  • oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, mineral oil, olive oil, sunflower oil, and fish-liver oil.
  • Solutions or suspensions can also include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • the pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
  • compositions may further comprise binders (e.g., acacia, cornstarch, gelatin, carbomer, ethyl cellulose, guar gum, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, povidone), disintegrating agents (e.g., cornstarch, potato starch, alginic acid, silicon dioxide, croscarmellose sodium, crospovidone, guar gum, sodium starch glycolate, Primogel), buffers (e.g., tris-HCL, acetate, phosphate) of various pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts), protease inhibitors, surfactants (e.g., sodium lauryl sulfate), permeation enhancers, solubilizing agents (e g., glycerol,
  • binders e
  • the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
  • the materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc.
  • Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
  • compositions can be included in a container, pack, or dispenser together with instructions for administration.
  • compositions that contain an active component are well understood in the art, for example, by mixing, granulating, or tablet-forming processes.
  • the active therapeutic ingredient is often mixed with excipients that are pharmaceutically acceptable and compatible with the active ingredient.
  • the active agents are mixed with additives customary for this purpose, such as vehicles, stabilizers, or inert diluents, and converted by customary methods into suitable forms for administration, such as tablets, coated tablets, hard or soft gelatin capsules, aqueous, alcoholic or oily solutions and the like as detailed above.
  • Those of ordinary skill in the art would be capable of determining dosing and dosing regimens for the different compounds appropriate for particular disease states and such dosing can be determined empirically.
  • the amount of a compound of the invention necessary to achieve the desired biological effect depends on a number of factors, for example the specific compound chosen, the intended use, the mode of administration and the clinical condition of the patient.
  • the daily dose is generally in the range from 0.3 mg to 500 mg (typically from 3 mg to 50 mg) per day and per kilogram of bodyweight, for example 3-10 mg/kg/day.
  • An intravenous dose may be, for example, in the range from 0.3 mg to 1.0 mg/kg, which can suitably be administered as slow infusion.
  • Single doses may contain, for example, from 1 mg to 10 g of the active ingredient.
  • ampoules for injections may contain, for example, from 1 mg to 100 mg
  • single-dose formulations which can be administered orally, such as, for example, tablets or capsules may contain, for example, from 0.05 to 1000 mg, typically from 0.5 to 500 mg.
  • the daily administration is then repeated continuously for a period of several days to several years.
  • Oral treatment may continue for between one week and the life of the patient.
  • the administration takes place for five consecutive days after which time the patient can be evaluated to determine if further administration is required.
  • the administration can be continuous or intermittent, i.e., treatment for a number of consecutive days followed by a rest period.
  • the compounds of the present invention may be administered intravenously on the first day of treatment, with oral administration on the second day and all consecutive days thereafter.
  • the amount of the compound administered to the patient is less than an amount that would cause toxicity in the patient. In the certain embodiments, the amount of the compound that is administered to the patient is less than the amount that causes a concentration of the compound in the patient's plasma to equal or exceed the toxic level of the compounds.
  • the compounds of formula (I) and (II) may be used as the compound itself, but they are preferably in the form of a pharmaceutical composition with an acceptable carrier.
  • the carrier must, of course, be acceptable in the sense that it is compatible with the other ingredients of the composition ⁇ and is not harmful for the patient's health.
  • the carrier may be a solid or a liquid or both and is preferably formulated with the compound as a single dose, for example as a tablet, which ⁇ may contain from 0.05% to 95% by weight of the active ingredient.
  • Other pharmaceutically active substances may likewise be present, including other compounds of the invention.
  • the ' pharmaceutical compositions of the invention can be produced by one of the known pharmaceutical methods, which essentially consist of mixing the ingredients with pharmacologically acceptable carriers and/or excipients.
  • compositions of the invention are those suitable for oral, rectal, topical, peroral (for example sublingual), intraperitoneal and parenteral (for example subcutaneous, intramuscular, intradermal or intravenous) administration, although the most suitable mode of administration depends in each individual case on the nature and severity of the condition to be treated and on the nature of the compound of formula (I) or (II) used in each case.
  • Coated formulations and coated slow-release, PEG, liposomal formulations also belong within the framework of the invention.
  • Suitable pharmaceutical compounds for oral administration may be in the form of separate units such as, for example, capsules, cachets, chewable tablets or tablets, each of which contain a defined amount of the compound of formula (I) or (II); as powders or granules; as solution or suspension in an aqueous or non aqueous liquid; or as an oil-in-water or water-in-oil emulsion.
  • These compositions may, as already mentioned, be prepared by any suitable pharmaceutical method which includes a step in which the active ingredient and the carrier (which may consist of one or more additional ingredients) are brought into contact.
  • the compositions are generally produced by uniform and homogeneous mixing of the active ingredient with a liquid and/or finely divided solid carrier, after which the product is shaped if necessary.
  • compositions which are suitable for peroral (sublingual) administration comprise chewable tablets which contain a compound of formula (I) or (II) with a flavoring, normally sucrose and gum arabic, and pastilles which comprise the compound in an inert base such as gelatin and glycerol or sucrose and gum arabic.
  • compositions suitable for parenteral administration comprise preferably sterile aqueous preparations of one or more of the compounds of general formulae (I) and (II), which are preferably isotonic with the blood of the intended recipient. These preparations are .preferably administered intravenously, although administration may also . take place by subcutaneous, intramuscular or intradermal injection. These preparations can preferably be produced by mixing the compound with water and making the resulting • solution sterile and isotonic with blood. Injectable compositions of the invention generally contain from 0.1 to 5% by weight of the active compound.
  • compositions suitable for rectal administration are preferably in the form of single-dose suppositories. These can be produced by mixing one or more of the compounds of general formulae (I) and (II) with one or more conventional solid carriers, for example cocoa butter, and shaping the resulting mixture.
  • compositions suitable for topical use on the skin are preferably in the form of ointment, cream, lotion, paste, spray, aerosol or oil.
  • Carriers which can be used are petrolatum, lanolin, polyethylene glycols, alcohols and combinations of two or more of these substances.
  • the active ingredient is generally present in a concentration of from 0.1 to 15% by weight of the composition, for example from 0.5 to 2%.
  • Transdermal administration is also possible.
  • Pharmaceutical compositions suitable for transdermal uses A suitable active ingredient concentration is about 1% to 35%, preferably about 3% to 15%.
  • the compounds of the formulae I and II are distinguished by favorable effects on metabolic disorders. They beneficially influence lipid and glucose metabolism, in particular they lower the triglyceride level and are suitable for the prevention and treatment of type II diabetes and arteriosclerosis and the diverse complications thereof.
  • Example 1 Assay for Potency of the Inhibitors of HSL Activity
  • Recombinant His-HSL was generated by cloning full-length rat HSL cDNA into the Smal site of p AcHLT- A containing a His6 tag.
  • p AcHLT- A-HSL (5 ⁇ g) was co-transfected into Sf21 cells with 0.5 ⁇ g of BaculoGoldTM DNA using the transfection kit from the manufacturer.
  • the titer of the recombinant virus was determined using an end point dilution assay, and the virus was re-amplified to a final titer of 1.5 x. 10 7 pfu/ml.
  • Sf21 cells were grown in 150mm Petri dishes and each 2 x 10 7 cells were infected with 100 ⁇ l of the high titer recombinant virus; cells were harvested three days after infection. After harvesting and cell extraction, His-HSL was purified on a Ni-agarose column.
  • HSL activity was determined as neutral cholesteryl ester hydrolase activity using a cholesteryl[14C]oleate emulsion for measurement of cellular activity, as described previously.
  • Substrate for the cholesteryl ester assay was prepared by adding 1.25 ⁇ Ci cholesteryl [l-14C]oleate (purified by thin-layer chromatography), 0.043 mmol phosphatidylcholine, and 0.011 mmol cholesteryl oleate into 2.5 mL of 100 mM potassium phosphate buffer (pH 7.0) containing 5 mM sodium taurocholate.
  • Inhibitors (fraction # O-4355, O-4350, O- 4361, O-4456, O-4457) were obtained from olives, olive oil, roots, bark and leaves from olea europeae species as previously described (Paiva-Martins et al., J. Agric.
  • Recombinant His-HSL is generated by cloning full-length rat HSL cDNA into the Smal site of p AcHLT-A containing a His6 tag.
  • pAcHLT- A-HSL is co-transfected into Sf21 cells with BaculoGoldTM DNA using the transfection kit from the manufacturer.
  • the titer of the recombinant virus is determined using an end point dilution assay.
  • Sf2t cells are grown in Petri dishes and cells are infected with the high titer recombinant virus and harvested three days after infection. After harvesting and cell extraction, His-HSL is purified on a Ni-agarose column.
  • HSL activity is determined as neutral cholesteryl ester hydrolase activity using a cholesteryl[14C]oleate emulsion for measurement of cellular activity, as described previously.
  • a substrate for the cholesteryl ester assay is prepared, vortexed and then sonicated for 3 hours with a Branson Sonifier/Cell Disruptor model W-350 on an output setting of 5.0 (50%). The substrate is then centrifuged to remove metallic fragments released by the probe and stored under nitrogen at 4°C.
  • Inhibitors e.g., fraction # O-4477
  • Inhibitors are obtained from olives, olive oil, roots, bark and leaves from olea europeae species as previously described (Paiva-Martins et al., J. Agric. Food Chem., 49:4214-4219, 2001) and dissolved in DMSO with distilled water. This is regarded as stock solution. 0-60 ⁇ L of the stock solution are added to the HSL assay to achieve a final concentration of 0-2.4 mg/ml of the inhibitors. The same volume of DMSO without inhibitors is performed as a control.
  • Assay for Potency of Inhibition on HSL Activity by the Inhibitors Aliquots of recombinant HSL protein and various concentrations of inhibitors are mixed and the volume adjusted to 100 ⁇ L. After the addition of the substrate, the assay is carried out at 37°C for 60 min. The reaction is stopped by the addition of chloroforrn:rnethanol:heptane (250:230:180). After the addition of borate/carbonate buffer (0.1 M, pH 10.5), the tubes are vortexed and centrifuged, and aliquots of the upper phase are taken for liquid scintillation counting in a Beckman scintillation counter.
  • Example 3 Assay for Potency of other Inhibitors of HSL Activity
  • Example 1 The experiment provided in Example 1 was repeated with other potential inhibitors (e.g., fraction # O-4356, O-4357, O-4358, 0-4359, O-4360, O-4349, O-4351, O-4352, O- 4353, 0-4363, O-4362, O-4364, O-4365, O-4354, O-4348, O-4366, O-4367, 0-4355, O-4350 and O-4361) to assess the inhibitor's affect on HSL activity.
  • other potential inhibitors e.g., fraction # O-4356, O-4357, O-4358, 0-4359, O-4360, O-4349, O-4351, O-4352, O- 4353, 0-4363, O-4362, O-4364, O-4365, O-4354, O-4348, O-4366, O-4367, 0-4355, O-4350 and O-4361
  • Recombinant His-HSL was generated by cloning full-length rat HSL cDNA into the Smal site of pAcHLT-A containing a His6 tag.
  • pAcHLT- A-HSL is co-transfected into Sf21 cells with BaculoGoldTM DNA using the transfection kit from the manufacturer.
  • the titer of the recombinant virus was determined using an end point dilution assay.
  • S£21 cells were grown in Petri dishes and cells were infected with the high titer recombinant virus and harvested three days after infection. After harvesting and cell extraction, His-HSL was purified on a Ni-agarose column.
  • HSL activity was determined as neutral cholesteryl ester hydrolase activity using a cholesteryl[14C]oleate emulsion for measurement of cellular activity, as described previously.
  • a substrate for the cholesteryl ester assay was prepared, vortexed and then sonicated for 3 hours with a Branson Sonifier/Cell Disruptor model W-350 on an output setting of 5.0 (50%). The substrate was then centrifuged to remove metallic fragments released by the probe and stored under nitrogen at 4°C
  • Inhibitors e.g., fraction # O-4356, O-4357, O-4358, O-4359, O-4360, O-4349, O-4351, O-4352, O-4353, O-4363, O-4362, O-4364, O- 4365, 0-4354, O-4348, O-4366, O-4367, O-4355, O-4350, O-4361 and O-4477
  • Inhibitors were obtained from olives, olive oil, roots, bark and leaves from olea europeae species as previously described (Paiva-Martins et al., J. Agric.
  • Analytical HPLC was performed using an Apollo Cis 150 mm x 4.6 mm / 5 ⁇ m column coupled with an Agilent 1050 series VWD UV detector at 254 nm. Conditions: Solvent A: H 2 O/0.1% TFA; Solvent B: acetonitrile, flow rate 1.5 mL/min.

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés constituant des inhibiteurs de la lipase hormono-sensible. La présente invention concerne également l’utilisation des composés et dérivés pour inhiber la lipase hormono-sensible, diverses compositions pharmaceutiques comprenant les composés et des procédés de traitement utilisant ces composés et compositions.
PCT/US2007/000284 2006-01-05 2007-01-05 Composes et derives pour le traitement d’etats medicaux par modulation de l’activite de la lipase hormono-sensible WO2007081808A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2007205147A AU2007205147A1 (en) 2006-01-05 2007-01-05 Compounds and derivatives for the treatment of medical conditions by modulating hormone-sensitive lipase activity
EP07717778A EP2015763A2 (fr) 2006-01-05 2007-01-05 Composes et derives pour le traitement d etats medicaux par modulation de l activite de la lipase hormono-sensible

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75637606P 2006-01-05 2006-01-05
US60/756,376 2006-01-05
US80033806P 2006-05-15 2006-05-15
US60/800,338 2006-05-15

Publications (2)

Publication Number Publication Date
WO2007081808A2 true WO2007081808A2 (fr) 2007-07-19
WO2007081808A3 WO2007081808A3 (fr) 2008-04-03

Family

ID=38256928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/000284 WO2007081808A2 (fr) 2006-01-05 2007-01-05 Composes et derives pour le traitement d’etats medicaux par modulation de l’activite de la lipase hormono-sensible

Country Status (4)

Country Link
US (1) US20070299129A1 (fr)
EP (1) EP2015763A2 (fr)
AU (1) AU2007205147A1 (fr)
WO (1) WO2007081808A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008001240A2 (fr) * 2006-06-29 2008-01-03 Kimberly-Clark Worldwide, Inc. Administration transdermique d'oléocanthal pour le soulagement de l'inflammation
WO2009009287A2 (fr) * 2007-07-12 2009-01-15 Deviris Inc. Modulateurs de lipase sensible aux hormones et procédés d'utilisation
FR2920668A1 (fr) * 2007-09-06 2009-03-13 Girex Soc Par Actions Simplifi Utilisation de l'oleocanthal pour le traitement des troubles du metabolisme lipidique
WO2009063378A3 (fr) * 2007-11-12 2009-10-15 Kimberly-Clark Worldwide, Inc. Formulation à l'huile d'olive destinée à soulager la douleur
WO2014138426A2 (fr) * 2013-03-07 2014-09-12 Topokine Therapeutics, Inc. Procédés et compositions pour la réduction de la graisse corporelle et des adipocytes
ES2690412R1 (es) * 2017-03-10 2019-02-08 Univ Sevilla Procedimiento para la obtención de secoiridoides dialdehídicos
ES2693177R1 (es) * 2017-03-10 2019-02-20 Univ Sevilla Procedimiento para la obtención de secoiridoides dialdehídicos

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050271755A1 (en) * 2004-05-12 2005-12-08 Ilya Raskin Phytomedicinal compositions for the control of lipid accumulation and metabolism in mammals

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050271755A1 (en) * 2004-05-12 2005-12-08 Ilya Raskin Phytomedicinal compositions for the control of lipid accumulation and metabolism in mammals

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDREWES ET AL.: 'Sensory properties of virgin olive oils polyphenols: Identification of deacetoxy-ligstroside aglycon as a key contributor to pungency' JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY vol. 51, 25 January 2003, pages 1415 - 1420 *
SAITTA ET AL.: 'Gas chromatographic-tandem mass spectrometric identification of phenolic compounds in silician olive oils' ANALYTICA CHIMICA ACTA vol. 466, 2002, pages 335 - 344 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879344B2 (en) 2006-06-29 2011-02-01 Kimberly-Clark Worldwide, Inc. Transdermal delivery of oleocanthal for relief of inflammation
WO2008001240A3 (fr) * 2006-06-29 2008-02-21 Kimberly Clark Co Administration transdermique d'oléocanthal pour le soulagement de l'inflammation
WO2008001240A2 (fr) * 2006-06-29 2008-01-03 Kimberly-Clark Worldwide, Inc. Administration transdermique d'oléocanthal pour le soulagement de l'inflammation
WO2009009287A2 (fr) * 2007-07-12 2009-01-15 Deviris Inc. Modulateurs de lipase sensible aux hormones et procédés d'utilisation
WO2009009287A3 (fr) * 2007-07-12 2009-03-19 Deviris Inc Modulateurs de lipase sensible aux hormones et procédés d'utilisation
FR2920668A1 (fr) * 2007-09-06 2009-03-13 Girex Soc Par Actions Simplifi Utilisation de l'oleocanthal pour le traitement des troubles du metabolisme lipidique
WO2009066021A1 (fr) * 2007-09-06 2009-05-28 B.C. Development S.A Utilisation de l'oleocanthal pour le traitement des troubles du metabolisme lipidique
WO2009063378A3 (fr) * 2007-11-12 2009-10-15 Kimberly-Clark Worldwide, Inc. Formulation à l'huile d'olive destinée à soulager la douleur
AU2008322390B2 (en) * 2007-11-12 2013-10-10 Kimberly-Clark Worldwide, Inc. Olive oil formulation for pain relief
AU2008322390C1 (en) * 2007-11-12 2014-01-23 Kimberly-Clark Worldwide, Inc. Olive oil formulation for pain relief
WO2014138426A2 (fr) * 2013-03-07 2014-09-12 Topokine Therapeutics, Inc. Procédés et compositions pour la réduction de la graisse corporelle et des adipocytes
WO2014138426A3 (fr) * 2013-03-07 2014-10-30 Topokine Therapeutics, Inc. Procédés et compositions pour la réduction de la graisse corporelle et des adipocytes
ES2690412R1 (es) * 2017-03-10 2019-02-08 Univ Sevilla Procedimiento para la obtención de secoiridoides dialdehídicos
ES2693177R1 (es) * 2017-03-10 2019-02-20 Univ Sevilla Procedimiento para la obtención de secoiridoides dialdehídicos
EP3594198A4 (fr) * 2017-03-10 2021-09-08 Universidad De Sevilla Utilisation du dmso pour la synthèse d'oléacéine et d'oléocanthal

Also Published As

Publication number Publication date
US20070299129A1 (en) 2007-12-27
EP2015763A2 (fr) 2009-01-21
WO2007081808A3 (fr) 2008-04-03
AU2007205147A1 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
JP6622824B2 (ja) キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法
EP2015763A2 (fr) Composes et derives pour le traitement d etats medicaux par modulation de l activite de la lipase hormono-sensible
WO2016022742A1 (fr) Composés bicycliques antidiabétiques
EP3757107A1 (fr) Composés de 4-oxo-3,4-dihydrothieno[3,4-d]pyridazine comme inhibiteurs d'aldose réductase et leurs procédés d'utilisation
EP3508483A1 (fr) Composé de dihydropyrimidine, son procédé de préparation et son utilisation
JP6302102B2 (ja) ベニコウジカビ（ｍｏｎａｓｃｕｓ ｐｕｒｐｕｒｅｕｓ）から単離された化合物、その調製方法及び使用
EP2865666B1 (fr) Dérivés hexahydropentaléno, leur procédé de préparation et leur utilisation en médecine
WO2009009287A2 (fr) Modulateurs de lipase sensible aux hormones et procédés d'utilisation
EP3992195A1 (fr) Régulateur du récepteur x du foie spiro (3,3'-isopropyl pyrrolidine), son procédé de préparation et son utilisation
CN114685488A (zh) 作为sos1抑制剂的化合物及其应用
EP3383388A1 (fr) Utilisation d'arylacylsulfonamides en tant qu'antagonistes de blt1
EP3953334B1 (fr) Nouvelles options synthétiques pour la fabrication de (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl) phényl]-6-oxo-1(6h)-pyrimidinyl}1-(difluorométhyl)-6-méthyl-1,4,7,8,9,10-hexahydro-11,15- (metheno)pyrazolo [4,3-b] [1,7] diazacyclotétradecin-5 (6h)-one
CN103494806B (zh) 苯骈α-吡喃酮类化合物的应用及其制备方法
WO2011156246A1 (fr) Nouveaux inhibiteurs de prolylcarboxypeptidase
JP6686032B2 (ja) 化合物、その分離方法、合成方法及び使用
RU2768451C1 (ru) Селективный антагонист рецепторов типа A2A
EP2519507B1 (fr) Dérivés d'aminoalcohol et leur utilisation thérapeutique
WO2023098588A1 (fr) Composé lactame macrocyclique d'origine marine, polaire, son procédé de préparation et son utilisation
WO2023040937A1 (fr) Promédicament de dérivés de pyrrolidone en tant qu'activateur de glucokinase
CN113620887A (zh) 一类sirt5蛋白抑制剂及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007717778

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007205147

Country of ref document: AU

Ref document number: 574414

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2007205147

Country of ref document: AU

Date of ref document: 20070105

Kind code of ref document: A